GidalBEPriviteraMDShethRDOilmanJT. Vigabatrin: A novel therapy for seizure disorders. Ann Pharmacother1999;33: 1277–86.
2.
KatzR. The domestic drug regulatory process: Why time is of the essence. In: FrenchJADichterMALeppikIE, eds. New antiepileptic drag developments. Amsterdam: Elsevier Science, 1993: 91–106.
3.
EkeTTalbotJFLawdenMC. Severe persistent visual field constriction associated with vigabatrin (letter). BMJ1997;314: 180–1.
4.
MackenzieRKlistornerA. Asymptomatic as well as symptomatic defects occur with vigabatrin (letter). BMJ1998;316: 233.
5.
HardingGFA. Severe persistant visual field constriction associated with vigabatrin. BMJ1998;316: 232–3.
6.
KraussGLJohnsonMAMillerNR. Vigabatrin-associated retinal cone system dysfunction: Electroretinogram and ophthalmologic findings. Neurology1998;50: 614–8.
7.
MllerNRJohnsonMAPaulSRGirkinCAPerryJDEndresMVisual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings. Neurology1999, in press.
8.
KalviainenRNousiainenIMantyjarviMNikoskelainenEPartanenJPartanenKVigabatrin, a gabaergic antiepileptic drag, causes concentric visual field defects. Neurology1999;53:922–6.
9.
SankarRWasterlainCG. Is the devil we know the lesser of two evils? Vigabatrin and visual fields. Neurology1999;52: 1537–8.
10.
HauserWAAnnegersJFElvebackLR. Mortality in patients with epilepsy. Epilepsia1980;21: 399–421.
11.
CramerJAFisherRBen-MenachemEFrenchJMattsonRH. New antiepileptic drags: Comparison of key clinical trials. Epilepsia1999;40: 590–600.
12.
BeranRHungAPlunkettMCurrieJSachinwallaT. Predictability of visual field defects in patients exposed to GABAergic agents, vigabatrin, or tiagabine (abstract). Neurology1999;52 (suppl 2):A249.
13.
KalviainenRNousiainenIMantyjarviMRiekkinenP. Absence of concentric visual field defects in patients with initial tiagabine monotherapy (abstract). Epilepsia1999;40 (suppl 2):A259.
